Trials / Terminated
TerminatedNCT03044249
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Mediti Pharma Inc. · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-101 | Capsules |
| DRUG | Placebo | Capsules |
Timeline
- Start date
- 2017-05-04
- Primary completion
- 2020-01-30
- Completion
- 2020-01-30
- First posted
- 2017-02-06
- Last updated
- 2021-04-01
- Results posted
- 2021-04-01
Locations
20 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03044249. Inclusion in this directory is not an endorsement.